CABALETTA BIO, INC. Current Liabilities
CABALETTA BIO, INC. (CABA) had Current Liabilities of $39.91 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Liabilities, Current $39.91M.
- 2026-03-31: Liabilities, Current $41.51M.
- 2025-12-31: Liabilities, Current $50.15M.
- 2025-09-30: Liabilities, Current $45.73M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $39.91M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $41.51M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $50.15M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $45.73M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $41.54M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $33.99M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $27.09M 10-K · filed 2026-03-23 |
| 2024-09-30 | $22.88M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $17.90M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $17.97M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $15.99M 10-K · filed 2025-03-31 |
| 2023-09-30 | $10.62M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $8.48M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $9.30M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $9.49M 10-K · filed 2024-03-21 |
| 2022-09-30 | $5.80M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $6.49M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $6.93M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $8.38M 10-K · filed 2023-03-16 |
| 2021-09-30 | $6.02M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $5.60M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $3.97M 10-Q · filed 2021-05-03 |
| 2020-12-31 | $5.18M 10-K · filed 2022-03-17 |
| 2020-09-30 | $4.26M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $3.26M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $3.26M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $3.15M 10-K · filed 2021-03-16 |
| 2019-09-30 | $3.06M 10-Q · filed 2019-12-05 |
| 2018-12-31 | $943.00K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |